Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)

  • Authors:
    • Qiuyue Chen
    • Jie Yi
    • Yiwei Liu
    • Chenglin Yang
    • Yujie Sun
    • Juan Du
    • Yi Liu
    • Dejian Gu
    • Hao Liu
    • Yingchun Xu
    • Yu Chen
  • View Affiliations

  • Published online on: July 2, 2024     https://doi.org/10.3892/mmr.2024.13277
  • Article Number: 153
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

 As sequencing technology transitions from research to clinical settings, due to technological maturity and cost reductions, metagenomic next‑generation sequencing (mNGS) is increasingly used. This shift underscores the growing need for more cost‑effective and universally accessible sequencing assays to improve patient care and public health. Therefore, targeted NGS (tNGS) is gaining prominence. tNGS involves enrichment of target pathogens in patient samples based on multiplex PCR amplification or probe capture with excellent sensitivity. It is increasingly used in clinical diagnostics due to its practicality and efficiency. The present review compares the principles of different enrichment methods. The high positivity rate of tNGS in the detection of pathogens was found in respiratory samples with specific instances. tNGS maintains high sensitivity (70.8‑95.0%) in samples with low pathogen loads, including blood and cerebrospinal fluid. Furthermore, tNGS is effective in detecting drug‑resistant strains of Mycobacterium tuberculosis, allowing identification of resistance genes and guiding clinical treatment decisions, which is difficult to achieve with mNGS. In the present review, the application of tNGS in clinical settings and its current limitations are assessed. The continued development of tNGS has the potential to refine diagnostic accuracy and treatment efficacy and improving infectious disease management. However, further research to overcome technical challenges such as workflow time and cost is required.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 30 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Q, Yi J, Liu Y, Yang C, Sun Y, Du J, Liu Y, Gu D, Liu H, Xu Y, Xu Y, et al: Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review). Mol Med Rep 30: 153, 2024.
APA
Chen, Q., Yi, J., Liu, Y., Yang, C., Sun, Y., Du, J. ... Chen, Y. (2024). Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review). Molecular Medicine Reports, 30, 153. https://doi.org/10.3892/mmr.2024.13277
MLA
Chen, Q., Yi, J., Liu, Y., Yang, C., Sun, Y., Du, J., Liu, Y., Gu, D., Liu, H., Xu, Y., Chen, Y."Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)". Molecular Medicine Reports 30.3 (2024): 153.
Chicago
Chen, Q., Yi, J., Liu, Y., Yang, C., Sun, Y., Du, J., Liu, Y., Gu, D., Liu, H., Xu, Y., Chen, Y."Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)". Molecular Medicine Reports 30, no. 3 (2024): 153. https://doi.org/10.3892/mmr.2024.13277